University of California, Los Angeles
ICOC Committed funds:
Awards as PI
|New Cell Lines||Generation of clinical grade human iPS cells||$1,382,400|
|Comprehensive Grant||Human Embryonic Stem Cell Therapeutic Strategies to Target HIV Disease||$2,516,831|
|Early Translational IV||Stem Cell Programming With Chimeric Antigen Receptors to Eradicate HIV Infection||$5,303,375|
Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice.
In Vivo Suppression of HIV by Antigen Specific T Cells Derived from Engineered Hematopoietic Stem Cells.
Introduction of Exogenous T-cell Receptors Into Human Hematopoietic Progenitors Results in Exclusion of Endogenous T-cell Receptor Expression.